2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155394
    RyRs activator 5 98%
    RyRs activator 5 (Compd A-1) is an active ryanodine receptor agonist against Spodoptera frugiperda.
    RyRs activator 5
  • HY-155456
    CYP2A6-IN-1 98%
    CD-6 is a flavonoid CYP2A6 inhibitor (IC50: 1.566 μM). CYP2A6 inhibits the metabolism of nicotine to cotinine, resulting in an increase in the amount of nicotine available in the blood, leading to increased smoking behavior. CD-6 mediates CYP2A6 inhibition and can be used in research on smoking cessation or smoking-related diseases.
    CYP2A6-IN-1
  • HY-15564R
    AR 231453 (Standard) 733750-99-7 98%
    AR 231453 (Standard) is the analytical standard of AR 231453. This product is intended for research and analytical applications. AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s.
    AR 231453 (Standard)
  • HY-15565R
    APD668 (Standard) 832714-46-2 98%
    APD668 (Standard) is the analytical standard of APD668. This product is intended for research and analytical applications. APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes.
    APD668 (Standard)
  • HY-155836
    hPL-IN-1 2387374-26-5 98%
    hPL-IN-1 (compound 2t) is a reversible inhibitor of pancreatic lipase (PL) (IC50=1.86 μM) for anti-obesity research.
    hPL-IN-1
  • HY-155985
    Anti-osteoporosis agent-6 445231-36-7 98%
    Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM.
    Anti-osteoporosis agent-6
  • HY-156073
    LY3325656 1998714-25-2
    LY3325656 is a selective GPR142 agonist. LY3325656 selectively activates GPR142. LY increases glucose-dependent insulin secretion. LY3325656 shows anti-diabetic effects. LY3325656 can be used in the research of type 2 diabetes.
    LY3325656
  • HY-156184
    Octanoylcarnitine 3671-77-0 98%
    Octanoylcarnitine is an orally active medium-chain acylcarnitine transport intermediate in fatty acid β-oxidation. Octanoylcarnitine is converted to octanoyl-CoA by carnitine acetyltransferase (CrAT), which then generates energy via β-oxidation in mitochondria of the heart and skeletal muscle. Octanoylcarnitine enhances grip strength and treadmill endurance, alleviates lactic acidosis, distributes in muscle and heart tissues, increases free carnitine levels, and mitigates mitochondrial stress. Octanoylcarnitine is associated with long-chain fatty acid metabolism, shows a positive correlation with subcutaneous fat area in patients with metastatic pancreatic ductal adenocarcinoma, and is closely related to central retinal artery occlusion (CRAO).
    Octanoylcarnitine
  • HY-15641R
    FG-2216 (Standard) 223387-75-5 98%
    FG-2216 (Standard) is the analytical standard of FG-2216. This product is intended for research and analytical applications. FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo.
    FG-2216 (Standard)
  • HY-15656R
    Ceritinib (Standard) 1032900-25-6 99.72%
    Ceritinib (Standard) is the analytical standard of Ceritinib (HY-15656). This product is intended for research and analytical applications. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
    Ceritinib (Standard)
  • HY-156690
    2-Quinizarincarboxylic acid 6416-55-3 98%
    2-Quinizarincarboxylic acid (Compound 15) is a glucose uptake inhibitor, with the inhibitory rate of 24.9% at 50 μM.
    2-Quinizarincarboxylic acid
  • HY-156916
    ST045945 93326-70-6 98%
    WAY-230563 (ST045945) is a serine/threonine kinase inhibitor that can block CHK1/CHK2-mediated cell cycle checkpoints. WAY-230563 can induce G2/M phase arrest and DNA damage in tumor cells.
    ST045945
  • HY-156923
    Glucokinase activator 5 536736-95-5 98%
    Glucokinase activator 5 (compound 6) is a glucokinase activator.
    Glucokinase activator 5
  • HY-156972
    NOP agonist-1 2099681-43-1 98%
    NOP agonist-1(compound 4) is a nociceptin opioid receptor (NOP) partial agonist. NOP agonist-1attenuate parkinsonian disabilities in 6-OHDA hemilesioned rats.
    NOP agonist-1
  • HY-156993
    NOP agonist-2 2099680-36-9 98%
    NOP agonist-2 is a selective NOP agonist.
    NOP agonist-2
  • HY-157253
    13(S)-HODE-biotin 1217458-58-6 98%
    13(S)-HODE is the lipoxygenase metabolite of Linoleic acid (HY-N0729). 13(S)-HODE modulates the platelet-activating factor, leukotriene B4, and formyl-Met-Leu-Phe-induced calcium influx in human polymorphonuclear leukocytes.
    13(S)-HODE-biotin
  • HY-157279
    16:0-18:2 PS sodium 384833-20-9 98%
    16:0-18:2 PS (sodium) is a phosphatidylserine.
    16:0-18:2 PS sodium
  • HY-157288
    (R)-Phe-A110/B319 98%
    (R)-Phe-A110/B319, a hapten, is a selective binder to tumor-associated antigens. (R)-Phe-A110/B319 has a 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex. (R)-Phe-A110/B319 can be used for the research of conditional chimeric antigen receptor T (CAR-T) cell activation and tumor targeting.
    (R)-Phe-A110/B319
  • HY-157306
    HC-1310 2101230-88-8 98%
    HC-1310 URAT1 Inhibitor (Compound 83) is a potent URAT1 inhibitor and can be used for research on hyperuricemia and gout.
    HC-1310
  • HY-157313
    Pancreatic lipase-IN-1 98%
    Pancreatic lipase-IN-1 (compound 8) ia a pancreatic lipase inhibitor with the Ki of 1.288 μM.
    Pancreatic lipase-IN-1
Cat. No. Product Name / Synonyms Application Reactivity